MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

InflaRx NV

Cerrado

0.79 3.95

Resumen

Variación precio

24h

Actual

Mínimo

0.75

Máximo

0.8

Métricas clave

By Trading Economics

Ingresos

-3.2M

-8.3M

BPA

-0.13

Margen de beneficio

1,208,456.738

Empleados

74

EBITDA

-3.2M

-8.2M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+575% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-59M

54M

Apertura anterior

-3.16

Cierre anterior

0.79

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

InflaRx NV Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 jul 2025, 23:55 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustments -- Market Talk

6 jul 2025, 22:35 UTC

Adquisiciones, fusiones, absorciones

South32 Expects to Complete Transaction in Late 2025

6 jul 2025, 22:35 UTC

Adquisiciones, fusiones, absorciones

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

6 jul 2025, 22:34 UTC

Adquisiciones, fusiones, absorciones

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

5 jul 2025, 04:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

4 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 15:57 UTC

Charlas de Mercado

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 jul 2025, 15:49 UTC

Charlas de Mercado

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Received All Required Authorizations

4 jul 2025, 15:48 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 jul 2025, 15:47 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Agreement Was Announced on Dec. 19

4 jul 2025, 15:47 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 jul 2025, 15:46 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 jul 2025, 14:30 UTC

Adquisiciones, fusiones, absorciones

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 jul 2025, 13:53 UTC

Charlas de Mercado

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 jul 2025, 13:41 UTC

Charlas de Mercado

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 jul 2025, 13:41 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 jul 2025, 13:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 12:37 UTC

Charlas de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 jul 2025, 12:37 UTC

Charlas de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus -2-

Comparación entre iguales

Cambio de precio

InflaRx NV Esperado

Precio Objetivo

By TipRanks

575% repunte

Estimación a 12 meses

Media 5.4 USD  575%

Máximo 10 USD

Mínimo 2 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para InflaRx NV Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

5

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.29 / 1.85Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de InflaRx NV

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.